Lineage Cell Therapeutics
LCTX
LCTX
104 hedge funds and large institutions have $89.1M invested in Lineage Cell Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Holders
104
Holding in Top 10
3
Calls
$64K
Puts
–
Top Buyers
| 1 | +$1.36M | |
| 2 | +$408K | |
| 3 | +$326K | |
| 4 |
Morgan Stanley
New York
|
+$148K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$119K |
Top Sellers
| 1 | -$1.05M | |
| 2 | -$979K | |
| 3 | -$391K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$197K |
| 5 |
Two Sigma Investments
New York
|
-$115K |